OptiNose's (OPTN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of OptiNose (NASDAQ:OPTN – Free Report) in a research note published on Monday, Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock. HC Wainwright also issued estimates for OptiNose’s Q1 2024 earnings at ($0.11) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 […]

Related Keywords

United States ,Michaelf Marino ,Onzetra Xsail ,Ramya Mahmoud ,Palumbo Wealth Management ,Highmark Wealth Management ,Optinose Inc ,York Mellon Corp ,Securities Exchange Commission ,Rice Hall James Associates ,Free Report ,Lake Street Capital ,Nose Trading Down ,Get Free Report ,Exchange Commission ,Wealth Management ,Mark Wealth Management ,New York Mellon Corp ,Rice Hall James ,Hall James ,Optinose Daily ,Optinose ,Nasdaq Optn ,Optn ,Medical ,Reiterated Rating ,Hc Wainwright ,